Understanding how a fungus becomes resistant to common medicines
Elevated gene transcription of the cyp51A gene is essential for azole drug resistance in Aspergillus fumigatus
This research aims to understand the genetic changes that make the Aspergillus fumigatus fungus resistant to antifungal drugs, which could help us find better ways to treat serious infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11131758 on NIH RePORTER |
What this research studies
Invasive Aspergillosis, a severe fungal infection caused by Aspergillus fumigatus, is very dangerous, especially when the fungus becomes resistant to standard antifungal medicines called azoles. This project looks closely at specific genetic changes in the fungus, particularly in a gene called cyp51A, which is a key target for azole drugs. We are exploring how a particular genetic alteration, a repeated section in the cyp51A gene, along with a protein called AtrR, helps the fungus resist treatment. By understanding these mechanisms, we hope to uncover new ways to overcome drug resistance and improve patient outcomes.
Who could benefit from this research
Good fit: This foundational research is relevant to patients suffering from invasive aspergillosis, particularly those with infections that are resistant to current antifungal medications.
Not a fit: Patients without fungal infections or those whose infections respond well to existing treatments may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new treatments or strategies to combat drug-resistant fungal infections, improving survival rates for patients with invasive aspergillosis.
How similar studies have performed: Previous work in this lab has identified key factors like the AtrR protein and specific genetic elements that contribute to drug resistance, building on existing knowledge in the field.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Moye-Rowley, W Scott — University of Iowa
- Study coordinator: Moye-Rowley, W Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.